A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Public ClinicalTrials.gov record NCT02564055. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the efficacy and safety of two concentrations (0.5 percent \[%\] and 1%) and two application frequencies (once a day and twice a day) of GSK2894512 cream for the topical treatment in adolescent and adult subjects with atopic dermatitis. Results from this study will be considered when selecting the most appropriate concentration of GSK2894512 cream and application frequency in future clinical studies. This is a multicenter (United States, Canada, and Japan), randomized, double-blind (sponsor-unblind), vehicle-controlled, 6-arm, parallel-group, dose-finding study in adolescent and adult subjects with atopic dermatitis. Two concentrations of GSK2894512 cream (0.5% and 1%) and a vehicle control cream will be equally randomized and evaluated following application to all atopic dermatitis lesions (except on the scalp) once daily (evening) or twice daily (morning and evening) for 12 weeks. This study will consist of 3 periods: up to 4 weeks screening, 12 weeks double-blind treatment, and 4 weeks post-treatment follow-up. The total duration of subject participation will be approximately 16 to 20 weeks. Approximately 270 adolescent and adult males and females subjects with atopic dermatitis will be screened in order to have at least 228 randomized subjects (38 subjects for each of the 6 treatment groups) and approximately 204 evaluable subjects overall. Approximately 30 subjects will be randomized in Japan to achieve at least 24 evaluable Japanese subjects.
Study identification
- NCT ID
- NCT02564055
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 247 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 1, 2015 (Type not available)
- Primary completion
- Jan 1, 2017 (Actual)
- Completion
- Jan 12, 2017 (Actual)
- Last update posted
- Nov 20, 2017
2015 – 2017
United States locations
- U.S. sites
- 36
- U.S. states
- 22
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Fort Smith | Arkansas | 72916 | — |
| GSK Investigational Site | Fresno | California | 93720-2933 | — |
| GSK Investigational Site | Irvine | California | 92697 | — |
| GSK Investigational Site | Los Angeles | California | 90045 | — |
| GSK Investigational Site | Oceanside | California | 92056 | — |
| GSK Investigational Site | Santa Ana | California | 92701 | — |
| GSK Investigational Site | Denver | Colorado | 80220 | — |
| GSK Investigational Site | North Logan | Connecticut | 06032 | — |
| GSK Investigational Site | Atlanta | Georgia | 30342 | — |
| GSK Investigational Site | Chicago | Illinois | 60611 | — |
| GSK Investigational Site | West Dundee | Illinois | 60118 | — |
| GSK Investigational Site | Indianapolis | Indiana | 46256 | — |
| GSK Investigational Site | New Albany | Indiana | 47150 | — |
| GSK Investigational Site | Overland Park | Kansas | 66215 | — |
| GSK Investigational Site | New Orleans | Louisiana | 70115 | — |
| GSK Investigational Site | Andover | Massachusetts | 01810 | — |
| GSK Investigational Site | Bay City | Michigan | 48706 | — |
| GSK Investigational Site | West Bloomfield | Michigan | 48322 | — |
| GSK Investigational Site | Fridley | Minnesota | 55432 | — |
| GSK Investigational Site | Saint Joseph | Missouri | 64506 | — |
| GSK Investigational Site | New York | New York | 10022 | — |
| GSK Investigational Site | High Point | North Carolina | 27262 | — |
| GSK Investigational Site | Cincinnati | Ohio | 45255 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19103 | — |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15213 | — |
| GSK Investigational Site | Cranston | Rhode Island | 2910 | — |
| GSK Investigational Site | Greer | South Carolina | 29650 | — |
| GSK Investigational Site | Dallas | Texas | 75230 | — |
| GSK Investigational Site | Dallas | Texas | 75231 | — |
| GSK Investigational Site | Houston | Texas | 77004 | — |
| GSK Investigational Site | Houston | Texas | 77056 | — |
| GSK Investigational Site | San Antonio | Texas | 78218 | — |
| GSK Investigational Site | San Antonio | Texas | 78229 | — |
| GSK Investigational Site | Webster | Texas | 77598 | — |
| GSK Investigational Site | Norfolk | Virginia | 23507 | — |
| GSK Investigational Site | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02564055, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 20, 2017 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02564055 live on ClinicalTrials.gov.